Wizemann, Theresa, Robinson, Sally, Giffin, Robert. "Appendix A: Agenda." Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press, 2008.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies - Workshop Summary
Are the current approaches for fulfilling these requirements adequate to advance development of drugs for rare or neglected diseases and individualized therapies?
Where along the continuum is investment needed?
Innovative Safe New Drugs—Financial Sectoring
TOM CASKEY (Drug Forum Member)
Chief Operating Officer and Director/Chief Executive Officer
University of Texas Health Science Center at Houston
Q&A
9:05
Session 1: Diverse Funding Organizations—Business Cases
Why were new approaches or models needed, and what are their advantages?
Are these models effective at helping to speed development and how might their impact be measured?
Are these viable models for advancing products in the context of individualized therapies?
Are federal regulatory policies adequate for helping speed development and approval of drugs for rare diseases?
Moderator:
TIMOTHY COETZEE
Executive Director
Fast Forward, LLC
9:10
OneWorld Health: A Not-for-Profit Pharmaceutical Company
VICTORIA HALE
Founder and Chair of the Board of Directors
Institute for OneWorld Health
9:25
Cystic Fibrosis Foundation Therapeutics’ Pipeline Approach toCFTR Drug Discovery and Development
